Peptide Injection Basics: Research Routes Explained

TL;DR

- Peptide injection basics starts with one fact: most research peptides are studied by subcutaneous (SC) injection because they break down in the gut and cross into blood poorly when swallowed. This page explains that research context, not how to inject anything. - In published trials, peptides like tesamorelin and PT-141 were administered subcutaneously (Falutz et al., 2007; Kingsberg et al., 2019). - A few peptide-like compounds are orally active. MK-677 (ibutamoren) is one, studied as a daily oral agent (Nass et al., 2008). - Lyophilized (freeze-dried) research peptides are typically reconstituted with a sterile diluent before study use. This is a handling step in the literature, not a reader instruction. - Nothing here is a dose, a schedule, or an administration guide. Any personal use question belongs with a qualified clinician.

Peptide injection basics: why is subcutaneous injection the default route?

Peptide injection basics comes down to one chemistry problem: peptides are chains of amino acids that the digestive system treats like food, so swallowing them usually destroys most of the compound before it reaches the blood.

Two problems drive this. First, enzymes in the stomach and small intestine cut peptide bonds, degrading the molecule. Second, even intact fragments cross the intestinal wall poorly because peptides are large and water-loving. The combined result is low oral bioavailability, which is why injectable routes are the default in most published peptide research.

Subcutaneous injection sidesteps the gut entirely. The compound enters the tissue layer just under the skin and is absorbed into circulation over time. This is the route used across many of the trials in the peptide literature. For example, tesamorelin was given by daily subcutaneous injection in its pivotal HIV lipodystrophy trial, where the primary endpoint was measured by CT scan (Falutz et al., 2007), and bremelanotide (PT-141) reached its approved use as a subcutaneous injection (Kingsberg et al., 2019).

This page is research context. It describes how studies administered these compounds. It is not a prescription, not a how-to, and not a schedule. Personal-use decisions route to a licensed clinician.

What does subcutaneous mean, and how does it differ from other routes?

Subcutaneous means "under the skin," into the fat layer between skin and muscle, and it differs from intramuscular (into muscle), intravenous (into a vein), and oral (swallowed) routes by how fast and how completely a compound reaches the blood.

Each route has a different absorption profile. Researchers pick the route that fits the compound's chemistry and the trial's goal. The table below summarizes what published trials in the seed literature actually used, framed as research-reported administration.

The point of the table is not what to take. It is to show that route is a study-design choice tied to each molecule, and that most peptide trials used the subcutaneous route while a small number of orally active compounds are the exception. Bremelanotide itself illustrates how route can shift across a development program: earlier research explored an intranasal formulation before the subcutaneous program that supported its approved use, another example of route being matched to the study, though the published early-route data is best read with caution.

Which peptides are the oral exceptions, and why?

A few compounds in the peptide and secretagogue class survive digestion well enough to work when swallowed, and MK-677 is the most cited example.

MK-677 (ibutamoren) is not a true peptide. It is a small non-peptide molecule that mimics the hormone ghrelin and stimulates growth hormone release. Because of its small-molecule structure, it is orally active and was studied as a once-daily oral agent (Nass et al., 2008). That same trial also reported metabolic tradeoffs: fasting glucose rose and insulin sensitivity fell, which is part of why route and safety are studied together, not separately.

The takeaway for the research reader: "oral peptide" is mostly a misnomer. The oral-active examples tend to be small mimetics rather than large peptide chains. True peptides in the literature are almost always injected because of the bioavailability problem above.

What is reconstitution, and why does the research literature mention it?

Reconstitution is the step of mixing a freeze-dried (lyophilized) peptide powder with a sterile liquid so it becomes a solution, and it appears in research handling because most research peptides ship as a dry powder for stability.

Peptides are more stable dry than in solution, so suppliers and labs store them lyophilized. Before a study can measure or administer a set amount, the powder is dissolved in a diluent, often bacteriostatic water (sterile water with a small amount of preservative). This is a laboratory preparation concept, described here so the term makes sense in research reading.

We are describing what the literature and handling protocols involve, not instructing anyone to prepare or inject anything. The mechanics of preparing a personal dose, choosing a volume, or administering a compound are clinical acts that belong with a qualified professional. For the concept of how powder amounts relate to solution amounts, see the linked units explainer below.

How does dosing get reported in peptide trials, and what does that mean here?

Trials report doses in real units from named studies, for example the 1.75 mg subcutaneous dose of PT-141 selected in its Phase 3 program (Kingsberg et al., 2019), and those figures describe what participants received under supervision, not a recommendation for anyone.

Reading a research dose is different from receiving a prescription. A trial dose was chosen for a specific population, monitored for safety, and reported as data. It is not a green light for self-administration. Every dosing figure on this site is framed as research-reported, and the personal-dose question is always routed to a clinician who can weigh an individual's health context.

Two practical reasons dosing detail matters even in a research-only reading: the same compound can be studied at different doses, and side effects often track with dose. PT-141 illustrates this, with nausea reported in 40.0 percent of participants on the 1.75 mg dose versus 1.3 percent on placebo in its Phase 3 trial data (Kingsberg et al., 2019), which underlines why supervision, not self-guessing, is the standard in the literature.